Day: September 10, 2025

SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced a proposed offering (the “Equity Offering”) relating to a total of up to 181,818,190 Class A ordinary shares of the Company, which consists of an offering of American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company (the “ADS Offering”) and an offering of Class A ordinary shares (the “Ordinary Share Offering”). The ADSs and/or Class A ordinary shares offered in the Equity Offering will be allocated between the ADS Offering and the Ordinary Share Offering based on investor interests. The Company intends to grant the underwriters in the Equity Offering a 30-day option to purchase up to an...

HighlightsDrill hole CS25-044 encountered three (3) spodumene pegmatite intervals, with the widest continuous interval of 457.4 metres, along with an additional 36.9 metre interval.Drill hole CS25-038 encountered 22 spodumene pegmatite intervals, including a 58.9 metre wide interval, along with a further 58.3 metre and 31.8 metre interval.Drill hole CS25-039 encountered 13 spodumene pegmatite intervals, including a 108.5 metre wide interval, along with a further 99.7 metre, 77.7 metre and 71.0 metre interval.Drill hole CS25-040 encountered 12 spodumene pegmatite intervals, including a 95.1 metre wide interval, along with a further 81.9 metre and 66.5 metre interval.A total of 46 holes for 20,138 metres have been drilled on the Cisco Project to date, with assays pending on the eight (8) holes drilled during the summer 2025 drill...

SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to integrate digital health services with innovative therapies in metabolic diseases and weight management. Fangzhou’s founder, chairman and CEO Dr. Xie Fangmin and Innovent Biologics Vice President of Retail Tan Zaiqiang attended the signing ceremony.Fangzhou signed a strategic partnership with Innovent Biologics The alliance will bring together Fangzhou’s AI-enabled “H2H” digital healthcare ecosystem and Innovent’s pipeline of novel therapies for diabetes and obesity, pioneering a new model that blends AI technology, innovative products and personalized services. The partnership comes as China’s...

LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) — DSEI EXPO – HII (NYSE: HII), America’s largest military shipbuilder, and a leader in advanced unmanned autonomous technology solutions, today announced the completion of production of the 750th REMUS unmanned undersea vehicle (UUV) for a customer. The German navy will receive the 750th REMUS, a REMUS 300, produced at the HII unmanned facility in Pocasset, Massachusetts. This marks the continued global adoption of REMUS systems to support national security and maritime operations. The REMUS line of UUVs is fielded in more than 30 countries, including 14 NATO members. Known for modularity, endurance, and proven performance, REMUS vehicles are deployed across defense, commercial, and research sectors for critical missions including mine countermeasures, hydrographic survey, intelligence...

LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII), America’s largest military shipbuilder, and Shield AI, the deep-tech company building state-of-the-art autonomy software products and aircraft, today announced a partnership to advance modular, cross-domain mission autonomy. The announcement was made in London at DSEI 2025, one of the world’s premier defense and security exhibitions. The partnership brings together Shield AI’s Hivemind mission autonomy software and HII’s Odyssey suite to develop next-generation autonomous solutions. By combining Shield AI’s advanced autonomy with HII’s decades of maritime expertise as America’s largest shipbuilder and leading global unmanned underwater vehicle provider, the two companies aim to accelerate autonomy across domains and platforms. “This partnership combines the very best of...

To Nasdaq Copenhagen A/S   New Final Bond Terms for Nykredit Realkredit A/S’s Base Prospectus dated 8 May 2025 In connection with the opening of new ISINs under Nykredit Realkredit A/S’s Base Prospectus dated 8 May 2025, Nykredit issues new Final Bond Terms. The Final Bond Terms for series 22H, 32G og 32H are stated below. Nykredit Realkredit A/S’s Base Prospectus dated 8 May 2025 and the relevant Final Bond Terms are available for download in Danish and English. In the event of discrepancies between the original Danish text and the English translation, the Danish text shall prevail. The documents can be found on Nykredit’s website at nykredit.com/ir.ISINSeries Currency Bond type Maturity IT/RF*DK0009551400 32H DKK Cibor3 + interest rate spread 01-10-2028 RFDK0009551590 32H DKK Cibor3 + interest rate...

VILVI Group, which consists of Vilkyškių pieninė AB, Modest AB, Kelmės pieninė AB, Kelmės pienas UAB, Pieno logistika AB and Baltic Dairy Board SIA, consolidated sales for August 2025 amounted EUR 24.11 million – 13.7% increase comparing to August 2024. The consolidated sales of the Group for period January – August 2025 amounted to EUR 191.53 million – 20.8% increase comparing to the same period last year.Vilija Milaseviciute          Economics and finance director Phone: +370 441 55 102 Email: vilija.milaseviciute@vilvi.eu

Press contact:Florence LievreTel.: +33 1 47 54 50 71Email: florence.lievre@capgemini.com On-Demand tech is on the rise, but spiraling costs, complexity, and governance gaps are putting returns at riskNearly eight in ten organizations say public cloud, Software-as-a-Service1 (SaaS) and Gen AI on cloud are key to drive growth, yet the same proportion are struggling to contain costs Three-quarters exceeded their public cloud budgets (by an average of 10%), while 68% overspent on Gen AI and 52% on SaaS Strategic cost management and FinOps2 maturity is essential to unlock their full potentialParis, September 10, 2025 – As digital transformation accelerates across industries, organizations are embracing On-Demand technologies — such as public cloud, Software-as-a-Service (SaaS), and Generative AI (Gen AI) — to scale innovation, improve...

Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at 11:30am CET. Attendance by registration only.  The format will be a panel discussion and open questions and answers (Q&A). The panel will include: Dr. Namir Hassan, CEO, Zelluna ASA, Moderator Prof. Bent Jakobsen, Pioneer of T Cell Receptor (TCR) therapy for cancer; former founder of two public TCR based companies including Immunocore. Zelluna ASA Board Member. Prof Fiona Thistlethwaite, Medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie,...